Researchers demonstrate rapid structural analysis of challenging drug target

Nuclera has announced the publication of research conducted in collaboration with researchers at the University of Cambridge’s Department of Biochemistry, demonstrating a rapid, cell-free approach utilising nanodisc technology to produce challenging protein drug-targets for high-resolution structural analysis.

The research, published as a preprint on bioRxiv, reports a 3.38Å resolution cryo-EM structure of an engineered human adenosine A2A receptor (A2AR) complex bound to an antagonist, with the workflow from initial gene assembly to cryo-EM sample preparation completed in four days. The findings demonstrate the potential to overcome a longstanding bottleneck in structural biology, enabling faster access to difficult to express proteins and supporting structure-based drug discovery.

GPCRs are a major class of therapeutic targets. While advances in cryo-EM have enabled increasingly detailed structural analysis, obtaining enough stable, correctly folded GPCRs remains a bottleneck, with conventional production and purification approaches often requiring extensive optimisation.

To address this, researchers combined Nuclera’s protein discovery system with the University of Cambridge’s cryo-EM expertise. Using cell-free protein synthesis, the team screened A2AR constructs against six lipid nanodisc conditions from Nuclera’s GPCR nanodisc panel to optimise protein expression. One of the highest-yielding conditions was then scaled up for purification, quality assessment and cryo-EM analysis. The resulting material enabled high-resolution structural analysis of the antagonist-bound A2AR complex, with the receptor architecture closely matching that of a conventionally produced reference.

To investigate the wider applicability of the approach, the researchers also produced and purified a further 12 GPCRs spanning Classes A, B and C, including six orphan receptors, for which endogenous activating ligands have not been identified. These additional proteins were assessed using fluorescence-detection size-exclusion chromatography (FSEC), demonstrating the potential to apply the production workflow across diverse GPCR targets, supporting further structural and biophysical investigations.

Dimitri Chirgadze, Cryo-EM facility manager, Department of Biochemistry, University of Cambridge, said: “Advances in cryo-EM have transformed our ability to investigate protein structures, but obtaining suitable samples remains a major challenge, particularly for complex membrane proteins. This research demonstrates that rapid, cell-free protein production can deliver high-quality, active protein suitable for high-resolution structural analysis, potentially opening up opportunities to investigate a wider range of challenging drug targets.”

Michael Chen, co-founder and chief scientific and business officer at Nuclera, said: “Access to membrane proteins remains a significant obstacle in drug discovery. By combining our cell-free protein synthesis and proprietary nanodisc technology with the University of Cambridge’s structural biology expertise, we have demonstrated a faster route to producing proteins suitable for high-resolution analysis. This represents an important step towards making difficult-to-study drug targets more accessible, with the potential to accelerate structural biology research and streamline future drug discovery.”

Nuclera will also host a webinar with Dimitri Chirgadze from the University of Cambridge on 15 December 2026, exploring the findings and their implications for GPCR structural biology.

Related Articles

- Advertisement -spot_img

Latest Articles